PATENT CLAIM ANALYSIS

Application Number: 15955960
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Claim (Index 1):
A method for reducing pancreatic cancer lesions, comprising administering a therapeutically effective amount of an anti-interleukin-6 (IL-6) receptor antibody and gemcitabine or a salt thereof to a subject in need thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.42105
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13700355', '12161733', '12085065', '12733951', '14812681']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6368361207759498
- 35 USC 102 Novelty (BERT): 0.4907546910848249
- Combined Prediction Score: 0.6222279778068373
- Mean Citation Score: 178.961924
- Max Citation Score: 216.78017000000003
- Similarity Product: 157.72454373749858

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test